Skip to main content
SpringerLink
Log in

Alemtuzumab

Papillary thyroid microcarcinoma: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • San KH, et al. Papillary thyroid microcarcinoma following alemtuzumab therapy for multiple sclerosis. Thyroid 28 (Suppl. 1): A98 abstr. 295, Oct 2018. Available from: URL: http://doi.org/10.1089/thy.2018.29065.abstracts [abstract] -USA

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab. Reactions Weekly 1733, 23 (2018). https://doi.org/10.1007/s40278-018-55822-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-55822-5

Search

Navigation